Expression and prognostic role of MEKK3 and pERK in patients with renal clear cell carcinoma

Asian Pacific Journal of Cancer Prevention

Volumn 16, Issue 6, 2015, Pages 2495-2499

  Chen, Qi ^a   Lu, Hong Sheng ^a   Gan, Mei Fu ^b   Chen, Lan Xi ^a   He, Kai ^a   Fan, Guang Min ^a   Cao, Xue Quan ^a  

^a TAIZHOU CENTRAL HOSPITAL   (China)

^b TAIZHOU HOSPITAL OF ZHEJIANG PROVINCE   (China)

Author keywords

FoxP3; MEKK3; PERK; Prognosis; Renal clear cell carcinoma

Indexed keywords

FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; MAP3K3 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 3; MONOCLONAL ANTIBODY; TUMOR MARKER;

ADULT; AGED; CANCER STAGING; CASE CONTROL STUDY; ENZYME IMMUNOASSAY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; IMMUNOLOGY; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PHOSPHORYLATION; PROGNOSIS; SURVIVAL RATE; T LYMPHOCYTE SUBPOPULATION; TISSUE MICROARRAY; TUMOR CELL CULTURE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; BIOMARKERS, TUMOR; CARCINOMA, RENAL CELL; CASE-CONTROL STUDIES; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOENZYME TECHNIQUES; KIDNEY NEOPLASMS; MALE; MAP KINASE KINASE KINASE 3; MIDDLE AGED; NEOPLASM STAGING; PHOSPHORYLATION; PROGNOSIS; SURVIVAL RATE; T-LYMPHOCYTE SUBSETS; TISSUE ARRAY ANALYSIS; TUMOR CELLS, CULTURED;

EID: 84929193402     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2015.16.6.2495     Document Type: Article

References (18)

1. Cao X, Lu H, Zhang L, et al (2014). MEKK3 and survivin expression in cervical cancer: association with clinicopathological factors and prognosis. Asian Pac J Cancer Prev, 15, 5271-76.
2. Christophe F, Sylvain M (2010). From basic research to clinical development of MEK 1/2 inhibitors for cancer therapy. J Hematol Oncol, 3, 3-8.
3. Chen L, Shi Y, Jiang CY, et al (2011). Expression and prog-nostic role of pan-Ras, Raf-1, pMEK1 and pERK1/2 in patients with hepatocellular carcinoma. EJSO, 37, 513-20
4. Cindy Neuzillet, Annemilaï Tijeras-Raballand, Louis de Mestier, et al (2014). MEK in cancer and cancer therapy. Pharmacol Ther, 141, 160-71.
5. Craig EA, Stevens MV, Vaillancourt RR, et al (2008). MAP3Ks as central regulators of cell fate during development. Developmental Dynamics, 237, 3102-14.
6. Escudier B, Eisen T, Stadler WM, et al (2007). SorMenib in advanced clear-cell renal-cell carcinoma. N Engl J Med, 356, l25-34.
7. Hanahan, D, Weinberg, RA (2011). Hallmarks of cancer: the next generation. Cell, 144, 646-74.
8. Kamal S, Sherene L, Evandro de Azambuja, et al (2013). Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. Cancer Treat Rev, 39, 935-46.
9. Lee HE, Park DJ, Kim WH, et al (2011). High FOXP3 regulatory t-cell density in the sentinel lymph node is associated with downstream non-sentinel lymph-node metastasis in gastric cancer. Br J Cancer, 34, 413-19.
10. Lu H, Cao X, Zhang H, et al (2014). Imbalance between MMP-2, 9 and TIMP-1 promote the invasion and metastasis of renal cell carcinoma via SKP2 signaling pathways. Tumor Biol, 35, 9807-13.
11. Lu H, Gan M, Zhang G, et al (2010). Expression of survivin, caspase-3 and p53 in cervical cancer assessed by tissue microarray: correlation with clinicopathology and prognosis. Eur J Gynaecol Oncol, 6, 662-66.
12. McCubrey JA, Steelman LS, Chappell WH, et al (2007). Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta, 1773, 1263-84.
13. Shinohara H, Yamasaki S, Maeda S, et al (2009). Regulation of NF-κB dependent T cell activation and development by MEKK3. Int Immunol, 21, 393-401
14. Wang G, Liu G, Liu Y, et al (2012). FOXP3 expression in esophageal cancer cells is associated with poor prognosis in esophageal cancer. Hepatogastroenterol, 59, 2186-91.
15. Wang X, Chang X, Su B, et al (2009). MEKK3 is essential for lymphopenia induced T cell proliferation and survival. J Immunol, 6, 3597-608.
16. Yoshimura K, Uemura H (2013). Role of vaccine therapy for renal cell carcinoma in the era of targeted therapy. Int J Urol, 20, 744-55.
17. Young A, Lou D, McCormick F (2013). Oncogenic and wild-type ras play divergent roles in the regulation of mitogen-activated protein kinase signaling. Cancer Discov, 1, 112-23.
18. Zeng C, Yao Y, Jie W, et al (2013). Up-regulation of Foxp3 participates in progression of cervical cancer. Cancer Immunol Immunother, 3, 481-7.